Calprotectin as an immune-dysregulation biomarker in amyotrophic lateral sclerosis: Insights for diagnosis and therapy [0.03%]
血清钙卫蛋白作为免疫失调生物标志物在肌萎缩侧索硬化症中的诊断和治疗价值研究
A Mendon,S Jain,N Mishra et al.
A Mendon et al.
Motor neuron degeneration is a defining feature of amyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disorder. Early diagnosis remains challenging due to the absence of reliable and validated biomarkers. Calprot...
V Hean,J-P Camdessanché
V Hean
Multiple sclerosis disability progression and predictors: A retrospective cohort study over five decades from a Canadian registry [0.03%]
加拿大登记处五十年来的多发性硬化残疾进展和预测指标：一项回顾性队列研究
T Quevillon,P-O Despault,P Duquette et al.
T Quevillon et al.
Background: Long-term disability progression data from Canadian multiple sclerosis (MS) populations remain limited. We examined disability progression patterns and prognostic factors in a large Canadian MS registry while ...
Movement disorders due to primary central nervous system lymphoma: An illustrative case and systematic literature review [0.03%]
原发中枢神经系统淋巴瘤所致运动障碍：一例报道及系统文献复习
V Harlay,V Mira,G Petrirena et al.
V Harlay et al.
Introduction: Movement disorders (MD) can result from various mechanisms: central nervous system infection (20%), trauma (15%), metabolic dysregulation (7%), vascular causes (22%), or inflammatory, degenerative, and tumor...
Isolated medial temporal lobe amnesia (MTLA): Predictor of cerebral amyloidosis or marker of phenotype-specific vulnerability? [0.03%]
孤立的海马旁区遗忘症（MTLA）：脑淀粉样变性的预示因子还是特定表型易感性的标志？
G Pin,T Horowitz,E Guedj et al.
G Pin et al.
Background: Medial temporal lobe amnestic syndrome (MTLA) is classically considered a hallmark of Alzheimer's disease (AD). However, emerging evidence suggests etiological heterogeneity, challenging the assumption that MT...
Prognosis biomarkers in MOGAD: What can we learn from observational studies? [0.03%]
视神经脊髓炎谱系疾病预后生物标志物的研究：我们能从观察性研究中获得什么？
B Lemarchant,P Cleuziou,S Rogeau et al.
B Lemarchant et al.
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a recently defined inflammatory demyelinating disease of the central nervous system, affecting both children and adults. MOGAD pathologically differs from mult...
How clinicians explain a diagnosis of functional neurological disorder: A qualitative study with general practitioners, neurologists, psychologists and physiotherapists [0.03%]
关于功能神经性障碍的临床解释：全科医生、神经学家、心理学家和理疗师的质性研究
E Marchica,L Vercueil,L Druart
E Marchica
Introduction: Functional neurological disorders (FND) are a frequent reason for consultation in neurology, characterized by symptoms that can impair various functions, without any identifiable lesion. Diagnosis plays a ke...
Simulated shared and supported decision making for amyloid immunotherapy in Alzheimer's disease: A bicentric study [0.03%]
针对阿尔茨海默病淀粉样蛋白免疫疗法的模拟共同决策和辅助决策：一项双中心研究
E Burry,F Plumacker,N Villain et al.
E Burry et al.
Lecanemab, the first anti-amyloid therapy approved by the European Medicines Agency, has demonstrated a statistically and clinically significant but moderate slowing of decline in early Alzheimer's disease (AD). In contrast, its long-term i...
DBS-related infections in Parkinson's disease: Incidence, risk factors, management and outcome [0.03%]
帕金森病相关脑起搏器感染的发病率、风险因素、处理及转归
M Desnoyers,M Bonjour,E Metereau et al.
M Desnoyers et al.
Background: Hardware-related infections may follow primary deep brain stimulation (DBS) implantation or implantable pulse generator (IPG) replacement with challenging management in fluctuating Parkinson's disease (PD) pat...